Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELAB PMGC	$1.93 +3.7%	$2.17	$1.81 ▼ $546.00	$2.87M	0.17	48,891 shs	48,203 shs
LGVN Longeveron	$0.76 +0.6%	$1.35	$0.63 ▼ $2.86	$11.54M	0.23	1.90 million shs	675,865 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
SNPX Synaptogenix	$8.40 -8.6%	$6.87	$1.84 ▼ $7.85	$11.68M	1.08	250,819 shs	249,702 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELAB PMGC	0.00%	+2.66%	-15.72%	-21.86%	-99.56%
LGVN Longeveron	0.00%	+12.11%	-50.65%	-46.48%	-70.88%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SNPX Synaptogenix	-8.65%	+36.36%	-9.77%	+288.89%	+125.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELAB PMGC	1.0107 of 5 stars	0.0	4.0	0.0	0.0	3.3	0.0	0.6
LGVN Longeveron	3.6784 of 5 stars	3.5	5.0	0.0	0.0	2.9	1.7	1.3
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELAB PMGC	0.00	N/A	N/A	N/A
LGVN Longeveron	3.00	Buy	$7.25	853.95% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
SNPX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELAB, PHXM, LGVN, and SNPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELAB PMGC	$1.71M	1.67	N/A	N/A	$6.09 per share	0.32
LGVN Longeveron	$2.07M	5.56	N/A	N/A	$0.83 per share	0.92
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELAB PMGC	-$6.25M	-$433.87	N/A	∞	N/A	N/A	-62.73%	-52.83%	N/A
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-894.40%	-95.91%	-79.69%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A

Latest ELAB, PHXM, LGVN, and SNPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELAB PMGC	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELAB PMGC	N/A	22.40	8.97
LGVN Longeveron	N/A	3.43	5.61
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
SNPX Synaptogenix	N/A	72.59	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELAB PMGC	22.22%
LGVN Longeveron	10.01%
PHXM PHAXIAM Therapeutics	0.40%
SNPX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
ELAB PMGC	0.60%
LGVN Longeveron	11.20%
PHXM PHAXIAM Therapeutics	1.94%
SNPX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELAB PMGC	18	1.48 million	1.48 million	N/A
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
SNPX Synaptogenix	4	1.39 million	1.35 million	Not Optionable

ELAB, PHXM, LGVN, and SNPX Headlines

Recent News About These Companies

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

July 1, 2025 | prnewswire.com

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

June 26, 2025 | prnewswire.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin

June 26, 2025 | kxan.comK

Synaptogenix begins TAO acquisition as part of crypto treasury strategy

June 26, 2025 | uk.investing.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA

June 26, 2025 | ktla.comK

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

June 24, 2025 | prnewswire.com

Synaptogenix Unveils TAO-Focused Crypto Treasury Plan

June 10, 2025 | livebitcoinnews.comL

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

June 9, 2025 | prnewswire.com

Synaptogenix Inc Ordinary Shares

January 3, 2025 | morningstar.comM

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

December 20, 2024 | prnewswire.com

Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary

October 7, 2024 | benzinga.com

Synaptogenix secures $5 million in preferred stock financing

September 13, 2024 | investing.com

Synaptogenix Announces $5.0 Million Financing

September 11, 2024 | prnewswire.com

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024

August 16, 2024 | investorplace.com

Synaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord Injury

July 19, 2024 | markets.businessinsider.com

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

July 18, 2024 | prnewswire.com

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

June 26, 2024 | prnewswire.com

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024

May 20, 2024 | investorplace.com

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024 | prnewswire.com

Synaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

April 24, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAB, PHXM, LGVN, and SNPX Company Descriptions

PMGC NASDAQ:ELAB

$1.93 +0.07 (+3.69%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.26%)

As of 08/15/2025 07:56 PM Eastern

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Longeveron NASDAQ:LGVN

$0.76 +0.00 (+0.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.74 -0.02 (-2.24%)

As of 08/15/2025 07:59 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/15/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Synaptogenix NASDAQ:SNPX

$8.40 -0.80 (-8.65%)

As of 08/15/2025

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time